In our in vivo experiment, the CAMP receptor antagonist indeed attenuated the TAM-associated tumor growth promotion effect, providing evidence that CAMP could serve as a potential target to inhibit breast cancer growth by disrupting the interaction between TAM andcancer cells. The gene discussed is CAMP; the disease is breast carcinoma.